ABT-702

• Description :

  ABT-702 is a potent, orally active, and selective adenosine kinase (AK) inhibitor with an IC50 of 1.7 nM. ABT-702 shows >1300-fold selectivity for AK over other biological targets, including cyclooxygenases-1 and -2. ABT-702 attenuates inflammation in diabetic retinopathy by increasing free adenosine levels. ABT-702 shows analgesic and anti-inflammatory effects in vivo. ABT-702 can be used for diabetic retinopathy research[1][2][3].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Adenosine Kinase; Adenosine Receptor

• Related Pathways :

  GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Neurological Disease; Inflammation/Immunology

• Purity :

  99.61

• Solubility :

  DMSO : 25 mg/mL (ultrasonic)

• Smiles :

  BrC1=CC=CC(C2=C3C(N)=NC=NC3=NC(C4=CC=C(N5CCOCC5)N=C4)=C2)=C1

• Molecular Formula :

  C22H19BrN6O

• Molecular Weight :

  463.33

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Jarvis MF, et al. ABT-702 (4-amino-5- (3-bromophenyl) -7- (6-morpholinopyridin-3-yl) pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse. J Pharmacol Exp Ther. 2000 Dec;295 (3) :1156-64.|[2]Parkinson FE, et al. The Effect of Endogenous Adenosine on Neuronal Activity in Rats: An FDG PET Study. J Neuroimaging. 2016 Jul;26 (4) :403-5.|[3]Elsherbiny NM, et al. ABT-702, an adenosine kinase inhibitor, attenuates inflammation in diabetic retinopathy. Life Sci. 2013 Jul 30;93 (2-3) :78-88.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [214697-26-4]